Literature DB >> 12630976

The distribution and gender difference of CYP3A activity in Chinese subjects.

Bing Zhu1, Zhao-Qian Liu, Guo-Lin Chen, Xiao-Ping Chen, Dong-Sheng Ou-Yang, Lian-Sheng Wang, Song-Lin Huang, Zhi-Rong Tan, Hong-Hao Zhou.   

Abstract

AIMS: To investigate the distribution of CYP3A activity in the Chinese population, and to test for gender-related differences in CYP3A activity.
METHODS: Using midazolam as a probe drug, CYP3A activity in 202 Chinese healthy subjects (104 men) was measured by plasma 1'-hydroxymidazolam:midazolam (1'-OH-MDZ:MDZ) ratio at 1 h after oral administration of 7.5 mg midazolam. The different phases of the menstrual cycle including preovulatory, ovulatory and luteal phases of 66 women phenotyped with midazolam were recorded. The concentrations of 1'-OH-MDZ and MDZ in plasma were measured by HPLC
RESULTS: A 13-fold variation of CYP3A activity (log1'-OH-MDZ:MDZ: range -0.949-0.203) was shown. The CYP3A activity was normally distributed as indicated by the frequency distribution histogram, the probit plot and the Kolmogorov-Smirnov test (P > 0.05). The CYP3A activity of women was higher than that of men (median: -0.36 vs -0.43, P < 0.05; 95% CI for difference: -0.127, -0.012). There was a significant difference in CYP3A activity between the three phases of the menstrual cycle. The activity was highest in the preovulatory phase and decreased sequentially in the ovulatory and luteal phases (P < 0.05).
CONCLUSIONS: A normal distribution of CYP3A activity was observed in the Chinese population. The CYP3A activity is higher in female subjects than in males. CYP3A activity differed across the phases of the menstrual cycle.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12630976      PMCID: PMC1884221          DOI: 10.1046/j.1365-2125.2003.01728.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  27 in total

Review 1.  Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.

Authors:  G R Wilkinson
Journal:  J Pharmacokinet Biopharm       Date:  1996-10

2.  Effect of age and gender on the activity of human hepatic CYP3A.

Authors:  C M Hunt; W R Westerkam; G M Stave
Journal:  Biochem Pharmacol       Date:  1992-07-22       Impact factor: 5.858

3.  Influence of age on the pharmacokinetics of alfentanil. Gender dependence.

Authors:  H J Lemmens; A G Burm; P J Hennis; M P Gladines; J G Bovill
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 4.  Noninvasive tests of CYP3A enzymes.

Authors:  P B Watkins
Journal:  Pharmacogenetics       Date:  1994-08

5.  Sequence of the 5'-flanking region of CYP3A5: comparative analysis with CYP3A4 and CYP3A7.

Authors:  Y Jounaïdi; P S Guzelian; P Maurel; M J Vilarem
Journal:  Biochem Biophys Res Commun       Date:  1994-12-30       Impact factor: 3.575

6.  Women in clinical trials of new drugs. A change in Food and Drug Administration policy. The Working Group on Women in Clinical Trials.

Authors:  R B Merkatz; R Temple; S Subel; K Feiden; D A Kessler
Journal:  N Engl J Med       Date:  1993-07-22       Impact factor: 91.245

7.  Relationship between hepatic cytochrome P450 3A content and activity and the disposition of midazolam administered orally.

Authors:  C Wandel; R H Böcker; H Böhrer; J X deVries; W Hofmann; K Walter; B Kleingeist; S Neff; R Ding; I Walter-Sack; E Martin
Journal:  Drug Metab Dispos       Date:  1998-02       Impact factor: 3.922

8.  Bimodal distribution of renal cytochrome P450 3A activity in humans.

Authors:  B D Haehner; J C Gorski; M Vandenbranden; S A Wrighton; S K Janardan; P B Watkins; S D Hall
Journal:  Mol Pharmacol       Date:  1996-07       Impact factor: 4.436

Review 9.  Gender effects in pharmacokinetics and pharmacodynamics.

Authors:  R Z Harris; L Z Benet; J B Schwartz
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

10.  Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: probe of CYP3A.

Authors:  J A Carrillo; S I Ramos; J A Agundez; C Martinez; J Benitez
Journal:  Ther Drug Monit       Date:  1998-06       Impact factor: 3.681

View more
  21 in total

Review 1.  Cytochrome P450 3A and their regulation.

Authors:  Oliver Burk; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-21       Impact factor: 3.000

2.  CYP3A phenotypes and genotypes in North Indians.

Authors:  Naushad Rais; Yogesh K Chawla; Krishan K Kohli
Journal:  Eur J Clin Pharmacol       Date:  2006-04-21       Impact factor: 2.953

Review 3.  Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds.

Authors:  E J Reschly; Matthew D Krasowski
Journal:  Curr Drug Metab       Date:  2006-05       Impact factor: 3.731

4.  The limited impact of CYP3A5 genotype for the pharmacokinetics of CYP3A substrates.

Authors:  Oliver Burk; Matthias Schwab
Journal:  Eur J Clin Pharmacol       Date:  2007-12       Impact factor: 2.953

5.  Cytochrome P4503A activity affects the gender difference in the development of steroid-induced osteonecrosis in rabbits.

Authors:  Satoshi Ikemura; Takuaki Yamamoto; Goro Motomura; Ryosuke Yamaguchi; Garida Zhao; Kenyu Iwasaki; Yukihide Iwamoto
Journal:  Int J Exp Pathol       Date:  2013-10-29       Impact factor: 1.925

6.  Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia.

Authors:  Qian Li; Yun Ai Su; Yi Liu; Jing Xu Chen; Yun Long Tan; Fu De Yang; Tian Mei Si
Journal:  Clin Pharmacokinet       Date:  2014-05       Impact factor: 6.447

7.  Effect of danshen extract on the activity of CYP3A4 in healthy volunteers.

Authors:  Furong Qiu; Guangji Wang; Rong Zhang; Jianguo Sun; Jian Jiang; Yueming Ma
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

8.  Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.

Authors:  Yogita Ghodke Puranik; Angela K Birnbaum; Susan E Marino; Ghada Ahmed; James C Cloyd; Rory P Remmel; Ilo E Leppik; Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2013-01       Impact factor: 2.533

9.  CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients.

Authors:  Wei Zhang; Yan-Zi Chang; Quan-Cheng Kan; Li-Rong Zhang; Zhi-Song Li; Hui Lu; Zhong-Yu Wang; Qin-Jun Chu; Jie Zhang
Journal:  Eur J Clin Pharmacol       Date:  2009-09-26       Impact factor: 2.953

10.  Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.

Authors:  M A Perera; R K Thirumaran; N J Cox; S Hanauer; S Das; C Brimer-Cline; V Lamba; E G Schuetz; M J Ratain; A Di Rienzo
Journal:  Pharmacogenomics J       Date:  2008-09-30       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.